← All startups
Iovance Biotherapeutics
Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.
Team21
NameLocationLinksContact
Dan Kirby
Chief Commercial Officer cco
—
—
Frederick G. Vogt
Interim CEO
—
—
Howard B. Johnson
Chief Business Officer
—
—
Igor Bilinsky
COO
—
—
Brian Shew
SVP Head of Digital
—
—
Kevin Smyth
Executive Vice President
—
—
Sara Pellegrino
—
—
Tracy Winton
EVP Human Resources
—
—
Michael Weiser
Director
—
—
Rana Fiaz M. D.
Executive Director
—
—
Ryan Maynard
Director
—
—
Wayne Rothbaum
Director
—
—
Wendy L. Yarno
Director
—
—
Hana Sahdev
Senior Securities
—
—
Kun Wang
Senior Patent Counsel
—
—
Athena Countouriotis
Board Member
—
—
Iain Dukes
Chairman of the Board
—
—
Kerry Elizabeth Wilson
Executive Counsel
—
—
Lauren Wilchek
Executive Counsel
—
—
Jonathan W.
Associate General Counsel
—
—
Sheila Ahern
Executive Assistant to CEO
—
—